Infirst Healthcare Limited

Biocopea Limited

Health Clinics Limited

Infirst Helathcare Limited

John Brew

Robin Mark Bannister

Wilson Caparros Wanderley

Richard R Reiley, Iii

Gregory Alan Stoloff

Suzanne Jane Dilly

Wilson Romero Caparros-Wanderley

Olga Pleguezuelos Mateo

Gemma Szucs

Wilson Caparros-Wanderely

Olga Pleguezeulos Mateo

Andrew Douglas Baxter

Richard Robert Reiley

Wilson CAPARRÓS-Wanderley

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in chronic inflammation

The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid in an amount of less than about 55%, one or more pharmaceutically-acceptable hard fats in an amount of at least 25% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of 1% to 50% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in severe pain

The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions comprising cannabidiols

Compositions and methods for treating severe pain

Compositions and methods for treating chronic inflammation and inflammatory diseases

The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Solid solution compositions and use in cardiovascular disease

The present specification discloses pharmaceutical compositions formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier comprising one or more free fatty acids, a glycerolipid, and a phospholipid as well as methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)

A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

Cancer drug and uses

Growing community of inventors

Hertfordshire, United Kingdom

John Brew